Trial Profile
A Phase II Study of the Proteasome Inhibitor PS-341 (NSC 681 239) in Patients With Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Nov 2007
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 29 Oct 2007 Status changed from in progress to completed.
- 17 Sep 2005 New trial record.